Clin2
NCT06727630Possibly a fitRecruiting

A study of PRJ1-3024 for advanced or spreading melanoma

Melanoma

Part of Cancer, Skin clinical trials.

This trial tests a new drug called PRJ1-3024 for people with advanced melanoma that has not responded to standard treatment. The goal is to see if the drug can shrink tumors or slow the cancer's growth.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
40 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have advanced melanoma that cannot be removed by surgery or has spread to other parts of the body
  • You have tried at least one standard treatment and it stopped working
  • You are at least 18 years old and able to take oral medications
  • You have a life expectancy of 3 months or more
  • You have adequate organ function (liver, kidneys, and blood cells)
  • You do not have certain other medical conditions like autoimmune disease or active infections

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06081920Recruiting· Phase 2
IBI363 for advanced melanoma after standard treatment

This study tests a new drug called IBI363 for people with advanced melanoma that has progressed after standard treatment. It aims to see if IBI363 can shrink tumors or slow their growth.

Beijing, Beijing Municipality
NCT05539118Not yet recruiting· Phase 1/Phase 2
Combination therapy for advanced melanoma

This trial tests a combination of three drugs (interferon, an immunotherapy drug called toripalimab, and an anti-cancer drug called anlotinib) in people with advanced melanoma that cannot be removed with surgery. The goal is to see if this combination can help shrink or control the cancer.

Xi'an, Shaanxi
NCT06246916Recruiting· Phase 3
Testing a new immunotherapy combo for advanced melanoma

This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.

Chandler, Arizona
NCT07480733Recruiting· Phase 2
Study of two drugs for advanced solid tumors

This trial tests two new drugs, JS212 and JS213, alone or together, for people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth.

Beijing, Beijing Municipality
NCT07310784Recruiting· Phase 2
Testing LM103 for advanced melanoma

This trial tests a new drug called LM103 for people with advanced melanoma who have already tried several standard treatments, including immunotherapy. The goal is to see if LM103 can help shrink tumors when other treatments have stopped working.

Beijing, Beijing Municipality
NCT06214156Recruiting· Phase 1/Phase 2
T3011 for advanced melanoma

This trial tests a new treatment, T3011, which is a virus that targets and kills cancer cells while also boosting your immune system. It's for people with advanced melanoma, and the goal is to see if it can shrink tumors and help you live longer.

Beijing

Hear when a new Melanoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.